Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

Kozlowski, 2006, Current and future issues in the manufacturing and development of monoclonal antibodies, Adv. Drug Deliv. Rev., 58, 707, 10.1016/j.addr.2006.05.002 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2004) ICH Harmonized Tripartite Guideline Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process (CPMP/ICH/5721/03), ICH, Geneva International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1999) ICH Harmonized Tripartite Guideline Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (CPMP/ICH/365/96), ICH, Geneva The European Agency for the Evaluation of Medicinal Products (2007) Guideline on Comparability of Biotechnology-derived Medicinal Products After a Change in the Manufacturing Process: Non-clinical and Clinical Issues (EMEA/CHMP/BMWP/101695/2006), EMA, London US Department of Health and Human Services Food and Drug Administration (2003). Guidance for Industry (draft): Comparability Protocols – Protein Drug Products and Biological Products – Chemistry, Manufacturing and Controls Information, FDA, Rockville, MD Center for Drug Evaluation and Research Center for Biologics Evaluation and Research (1996). FDA Guidance Concerning Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products, CBER, Rockville, MD Khawli, 2002, Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin, Cancer Biother. Radiopharm., 17, 359, 10.1089/108497802760363150 Hong, 1999, Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat, J. Pharm. Sci., 88, 147, 10.1021/js970335n Lee, 2003, Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging, Bioconj. Chem., 14, 546, 10.1021/bc0256648 Pardridge, 1996, Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice, J. Pharmacol. Exp. Ther., 276, 246 Dellian, 2000, Vascular permeability in a human tumour xenograft: molecular charge dependence, Br. J. Cancer, 82, 1513 Pardridge, 1995, Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization, J. Pharm. Sci., 84, 943, 10.1002/jps.2600840808 Lee, 2003, Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging, Bioconj. Chem., 14, 546, 10.1021/bc0256648 Harris, 2005, Heterogeneity of recombinant antibodies: linking structure to function, Dev. Biol. (Basel), 122, 117 Khawli, 1996, Improved tumor localization and radioimaging with chemically modified monoclonal antibodies, Cancer Biother. Radiopharm, 11, 203, 10.1089/cbr.1996.11.203 Igawa, 2010, Reduced elimination of IgG antibodies by engineering the variable region, Protein Eng. Des. Sel., 23, 385, 10.1093/protein/gzq009 Ghetie, 2000, Multiple roles for the major histocompatibility complex class I- related receptor FcRn, Annu. Rev. Immunol., 18, 739, 10.1146/annurev.immunol.18.1.739 Burton, 2006, Sugar determines antibody activity, Science, 313, 627, 10.1126/science.1131712 Jefferis, 2009, Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action, Trends Pharmacol. Sci., 30, 356, 10.1016/j.tips.2009.04.007 Scanlan, 2008, Making autoantibodies safe, Proc. Natl. Acad. Sci. U. S. A., 105, 4081, 10.1073/pnas.0801192105 Kanda, 2007, Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types, Glycobiology, 17, 104, 10.1093/glycob/cwl057 Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 Wright, 1998, Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells, J. Immunol., 160, 3393, 10.4049/jimmunol.160.7.3393 Jones, 2007, Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys, Glycobiology, 17, 529, 10.1093/glycob/cwm017 Li, 2009, Pharmacological significance of glycosylation in therapeutic proteins, Current Opin. Biotechnol., 20, 678, 10.1016/j.copbio.2009.10.009 Zhou, 2008, Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function, Biotechnol. Bioeng., 99, 652, 10.1002/bit.21598 Chen, 2009, The effect of Fc glycan forms on human IgG2 antibody clearance in humans, Glycobiology, 19, 240, 10.1093/glycob/cwn120 Raju, 2008, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Current Opin. Immunol., 20, 471, 10.1016/j.coi.2008.06.007 Hodoniczky, 2005, Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro, Biotechnol. Prog., 21, 1644, 10.1021/bp050228w Cleland, 1993, The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation, Crit. Rev. Ther. Drug Carrier Syst., 10, 307 Andya, 2003, Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations, AAPS PharmSci., 5, E10, 10.1208/ps050210 Liu, 2008, Heterogeneity of monoclonal antibodies, J. Pharm. Sci., 97, 2426, 10.1002/jps.21180 Moore, 1980, Role of aggregated human growth hormone (hGH) in development of antibodies to hGH, J. Clin. Endocrinol. Metab., 51, 691, 10.1210/jcem-51-4-691 Robbins, 1987, Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients, Diabetes, 36, 838, 10.2337/diabetes.36.7.838 Braun, 1997, Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice, Pharm. Res., 14, 1472, 10.1023/A:1012193326789 Hermeling, 2006, Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation, J. Pharm. Sci., 95, 1084, 10.1002/jps.20599 Ryff, 1997, Clinical investigation of the immunogenicity of interferon-alpha 2a, J. Interferon Cytokine Res., 17, S29 Kang, 1991, Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans, Diabetes Care, 14, 942, 10.2337/diacare.14.11.942 Pezron, 2002, Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3), J. Pharm. Sci., 91, 1135, 10.1002/jps.10114 Clodfelter, 1998, Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide, Pharm. Res., 15, 254, 10.1023/A:1011918719017 Pavlinkova, 1999, Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts, J. Nucl. Med., 40, 1536 Bleeker, 2000, Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase, Blood, 95, 1856, 10.1182/blood.V95.5.1856.005k03_1856_1861 US Department of Health and Human Services Food and Drug Administration (2001). Guidance for Industry: Statistical Approaches to Establishing Bioequivalence, FDA, Rockville, MD Lewis, 2010, Summary of DIA Workshop: Comparability Challenges: Regulatory and Scientific Issues in the Assessment of Biopharmaceuticals, Drug Information Journal, 44, 485, 10.1177/009286151004400413 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2000). ICH Harmonized Tripartite Guideline E10, Choice Of Control Group And Related Issues In Clinical Trials (CPMP/ICH/364/96), ICH, Geneva International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1994). ICH Harmonized Tripartite Guideline E4, Dose-Response Information to Support Drug Registration (CPMP/ICH/378/95), ICH, Geneva Newland, 2009, Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura, Eur. J. Haematol., 82, 20, 10.1111/j.1600-0609.2008.01209.x Kapetanovic, 2006, Predictors of infusion reactions during infliximab treatment in patients with arthritis, Arthritis Res. Ther., 8, R131, 10.1186/ar2020 Freedman, 2007, Neutralizing antibodies to biological therapies: A “touch of gray” vs a “black and white” story, Neurology, 69, 1386, 10.1212/01.wnl.0000282011.92098.68 Calabresi, 2007, The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL, Neurology, 69, 1391, 10.1212/01.wnl.0000277457.17420.b5 The European Agency for the Evaluation of Medicinal Products (2007). Guideline On Immunogenicity Assessment Of Biotechnology-Derived Therapeutic Proteins (EMEA/CHMP/BMWP/14327/2006), EMA, London Chirino, 2005, State of the art analytical comparability: a review, Dev. Biol. (Basel), 122, 3 Rathore, 2009, Follow-on protein products: scientific issues, developments and challenges, Trends Biotechnol., 27, 698, 10.1016/j.tibtech.2009.09.004 Shankar, 2007, A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, Nat. Biotechnol., 25, 555, 10.1038/nbt1303 Peipp, 2008, Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells, Blood, 112, 2390, 10.1182/blood-2008-03-144600 Phillips, 2004, A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis, Clin. Ther., 26, 511, 10.1016/S0149-2918(04)90053-7 Ferrara, 2006, The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms, J. Biol. Chem., 281, 5032, 10.1074/jbc.M510171200 Nimmerjahn, 2007, Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity, Proc. Natl. Acad. Sci. U. S. A., 104, 8433, 10.1073/pnas.0702936104 Shinkawa, 2003, The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity, J. Biol. Chem., 278, 3466, 10.1074/jbc.M210665200 Scallon, 2007, Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality, Mol. Immunol., 44, 1524, 10.1016/j.molimm.2006.09.005